BIND Therapeutics, Inc.

Industry

  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
      • Controlled Release

Other Names/Subsidiaries

  • BIND Biosciences, Inc.
See more in Biomedtracker

Latest on BIND Therapeutics, Inc.

Scrip

Scrip 100 Analysis: Sales Up, Profits Down – But Is It Real?

 
• By John Hodgson

The Scrip 100 examines the financial performance of all companies that sell more than $1m worth of prescription drugs or spend more than $1m on drug-related R&D. Confusingly, the universe of companies

Scrip

With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules

 
• By Mandy Jackson

Michael Gilman didn't have much time to enjoy "retirement" after Bristol-Myers Squibb Co. acquired his last company Padlock Therapeutics Inc. for up to $600m. Within months he was immersed in

In Vivo

Biopharma Quarterly Dealmaking Statistics, Q3 2016

 
• By Amanda Micklus and Maureen Riordan

Financings Third-quarter 2016 biopharma financing totaled $7.4 billion, a 54% increase over Q2’s $4.8 billion. Follow-on public offerings were again the lead financing vehicle, bringing in $3.36 billi

Pink Sheet

Deal Watch: Medivation Enters Confidential Talks With Suitors, Including Sanofi

 
• By Joseph Haas

The Pink Sheet regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between July 2-7. D